ArticleMedical sciences (Basel, Switzerland)2025
Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker.
Article in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Multidomain Prediction Model Integrating Myocardial Injury, Ventricular Function, and Inflammation for Short-Term Risk Stratification in Patients with NSTEMI.Clinics and practice · 2026Article
- The Hidden Burden of Depression in STEMI: Effects on Early Complications and 12-Month MACCE.Diagnostics (Basel, Switzerland) · 2026Article
- Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.Biomolecules · 2026Review
- Age-Dependent Inflammatory, Lipid, and Echocardiographic Phenotypes in Acute Myocardial Infarction: Associations with In-Hospital Adverse Clinical Events.Biomedicines · 2026Article
- Clinical and Inflammatory Determinants of Heart Failure Severity Following Myocardial Infarction: Implications for Post-Infarction Care.Journal of cardiovascular development and disease · 2026Article
- Insulin Resistance and Atherogenic Dyslipidemia Drive Cardiac Remodeling and Cardiovascular Events After Kidney Transplantation.Journal of clinical medicine · 2026Article
- Cholesterol-to-Lymphocyte Ratio as a Predictor of 1-Year Unplanned Readmission in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus: A Retrospective Cohort Study.International journal of general medicine · 2026Article
- The systemic immune-inflammation index in coronary heart disease: a narrative review of thromboinflammation, phenotype-dependent utility, and clinical translation.Frontiers in cardiovascular medicine · 2026Review
- The Systemic Immune-Inflammation Index as a Predictor of Clinical Outcomes in Chronic Coronary Syndrome: Influence of Diabetes Mellitus.Journal of inflammation research · 2026Article
- The association between systemic immune-inflammation index and mortality of elderly chronic bronchitis patients complicated by acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Predictive value of dynamic changes in RvD1, sST2, and PIV levels for the prognosis of STEMI patients after PCI: a prospective study.Frontiers in cardiovascular medicine · 2025Article
- The Red Cell Distribution Width/Albumin Ratio in STEMI: Biologically Plausible but Clinically Unproven.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesInflammation plays a key role in acute coronary syndromes (ACS). The systemic immune-inflammation index (SII), which integrates immune and inflammatory markers, may serve as a valuable prognostic tool. This study aimed to evaluate the utility of SII as a short-term predictor of mortality and major adverse cardiovascular and cerebral events (MACCE) in ACS patients.
methodsA retrospective analysis was conducted on 964 ACS patients admitted in 2023. SII was calculated from admission hematological parameters. Primary and secondary outcomes were 30-day mortality and MACCE, respectively.
resultsSII levels differed significantly across ACS subtypes (
conclusionsSII proved to be a cost-effective biomarker reflecting inflammation, immunity, and thrombosis. Elevated SII predicted short-term MACCE and mortality in ACS, with improved prognostic power when combined with GRACE 2. Persistent elevation may signal ongoing inflammation and increased MACCE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.